Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Atomo Diagnostics Limited
  6. News
  7. Summary
    AT1   AU0000080327

ATOMO DIAGNOSTICS LIMITED

(AT1)
  Report
Delayed Australian Stock Exchange  -  12:10:30 2023-02-06 am EST
0.0530 AUD    0.00%
01/17Atomo Diagnostics, NG Biotech Sign Commercialization Deal for Rapid Blood-based Pregnancy Tests; Shares Jump 4%
MT
01/17Atomo Diagnostics Limited and NG Biotech Sign New Commercialisation Agreement to Expand the Launch of A Unique Blood Based Rapid Pregnancy Test in Key Global Markets
CI
2022Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Atomo Diagnostics Limited Expands Executive Team

04/25/2022 | 10:06pm EST

Atomo Diagnostics Limited announced the expansion and strengthening of its executive commercial team and a change in the COO role to better support renewed international commercial focus and operations activity, the role now being headquartered in Sydney. Key elements include: Based in San Diego, California, Jim McMenamy joins Atomo as Head of Business Development and Partnerships, the Americas Based in the UK, Anna Tucker joins Atomo as Head of Business Development and Partnerships, Europe, Middle East and Africa (EMEA) Based in Sydney, Chandra Sukumar assumes the role of COO, building on her experience running product development and OEM product management with the company. UK based Mark Smith is departing as Atomo's COO and transitioning to a consulting role during a transition period.

Jim McMenamy has over 30 years of experience in the global POC diagnostics market having had roles with companies such as Becton Dickinson, Quidel Corp, ACON Laboratories, Inverness Medical, AGEN Biomedical, Samsung Diagnostics and Henry Schein Animal Health. Jim has held leadership roles in areas of Marketing, Sales, Business Development and General Management in global human and veterinary POC diagnostics markets for these organisations. Anna Tucker brings to Atomo a proven track record of developing businesses across the Life Sciences sector, with more than 25 years' experience working in sales, distribution management and field marketing globally.

As Director, Distributor Sales, EMEA at Congenica, Anna was responsible for driving revenue growth through the identification, selection and ongoing management of a network of distributors and expanding the commercial footprint of Congenica's diagnostic software and services business across EMEA. The promotion of Chandra Sukumar into the role of COO enables operational leadership to be based at Atomo's global headquarter based in Sydney. It also leverages her successful leadership directing Atomo's development programs for key platform programs such as Elion and our new integrated swab device (Blackburn), as well as her management of both technical and product support for Atomo's OEM customers, which is key as Atomo expands its market presence.


ę S&P Capital IQ 2022
All news about ATOMO DIAGNOSTICS LIMITED
01/17Atomo Diagnostics, NG Biotech Sign Commercialization Deal for Rapid Blood-based Pregnan..
MT
01/17Atomo Diagnostics Limited and NG Biotech Sign New Commercialisation Agreement to Expand..
CI
2022Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Directo..
CI
2022Atomo Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 202..
CI
2022Atomo Diagnostics Limited Signs Agreement with Hangzhou Alltest Biotech Co., Ltd, for S..
CI
2022Atomo Diagnostics Posts Higher Fiscal Q4 Revenue, Cash Receipts
MT
2022Atomo Diagnostics : Quarterly Activity Report - 30 June 2022
PU
2022Atomo Diagnostics : Notification regarding unquoted securities - AT1
PU
2022Atomo Diagnostics : Quarterly Activity Report - 31 March 2022
PU
2022Atomo Diagnostics Limited Expands Executive Team
CI
More news
Financials
Sales 2022 12,3 M 8,48 M 8,48 M
Net income 2022 -5,71 M -3,92 M -3,92 M
Net cash 2022 12,6 M 8,68 M 8,68 M
P/E ratio 2022 -5,58x
Yield 2022 -
Capitalization 30,3 M 20,8 M 20,8 M
EV / Sales 2021 12,9x
EV / Sales 2022 1,57x
Nbr of Employees -
Free-Float 64,3%
Chart ATOMO DIAGNOSTICS LIMITED
Duration : Period :
Atomo Diagnostics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATOMO DIAGNOSTICS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
John Kelly Chief Executive Officer, Director & MD
William Souter Chief Financial Officer
John P. Keith Non-Executive Chairman
Chandra Sukumar Chief Operating Officer
Paul Alexander Kasian Independent Non-Executive Director
Sector and Competitors